Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert M Califf

Showing results (291-300 of 770) with videos related to

Pageof 77
Sort By:
Annals of Internal Medicine|October 14, 2024
Opportunities for Innovation in Smoking Cessation Therapies: A Perspective From the National Institutes of Health and U.S. Food and Drug AdministrationHaider J Warraich, Brian A King, Wilson M Compton, et al.
Cardiac Electrophysiology Review|January 24, 2004
Significance of atrial fibrillation during acute myocardial infarction, and its current management: insights from the GUSTO-3 trialCheuk-Kit Wong, Harvey D White, Robert G Wilcox, et al.
Journal of the American College of Cardiology|October 30, 2007
Long-term outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated by shock: insights from the GUSTO-I trialMandeep Singh, Jennifer White, David Hasdai, et al.
Clinical Pharmacology and Therapeutics|April 25, 2021
When Can We Rely on Real-World Evidence to Evaluate New Medical Treatments?Gregory E Simon, Richard Platt, Jonathan H Watanabe, et al.
The American Journal of Cardiology|September 17, 2002
Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profileDean J Kereiakes, A Michael Lincoff, Keaven M Anderson, et al.
Medrxiv : the Preprint Server for Health Sciences|August 8, 2025
Racial and Ethnic Diversity in Clinical Studies Reported to ClinicalTrials.gov, 2009-2024Maryam Aziz, Emily C O'Brien, Jay B Lusk, et al.
American Heart Journal|September 14, 2002
Relationship between activated clotting time during percutaneous intervention and subsequent bleeding complicationsWilliam B Hillegass, Brigitta C Brott, Gregory D Chapman, et al.
Clinical Pharmacology and Therapeutics|May 1, 2021
When Can We Trust Real-World Data To Evaluate New Medical Treatments?Gregory E Simon, Andrew B Bindman, Nancy A Dreyer, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 10, 2013
The landscape of clinical trials in nephrology: a systematic review of Clinicaltrials.govJula K Inrig, Robert M Califf, Asba Tasneem, et al.
American Heart Journal|February 22, 2003
Development and validation of a simple model to predict severe coronary artery disease after myocardial infarction: potential impact on cardiac catheterization use in the United States and CanadaWayne B Batchelor, Daniel B Mark, J David Knight, et al.
Pageof 77

Showing results (291-300 of 770) with videos related to

Sort By:
Pageof 77
Annals of Internal Medicine|October 14, 2024
Opportunities for Innovation in Smoking Cessation Therapies: A Perspective From the National Institutes of Health and U.S. Food and Drug AdministrationHaider J Warraich, Brian A King, Wilson M Compton, et al.
Cardiac Electrophysiology Review|January 24, 2004
Significance of atrial fibrillation during acute myocardial infarction, and its current management: insights from the GUSTO-3 trialCheuk-Kit Wong, Harvey D White, Robert G Wilcox, et al.
Journal of the American College of Cardiology|October 30, 2007
Long-term outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated by shock: insights from the GUSTO-I trialMandeep Singh, Jennifer White, David Hasdai, et al.
Clinical Pharmacology and Therapeutics|April 25, 2021
When Can We Rely on Real-World Evidence to Evaluate New Medical Treatments?Gregory E Simon, Richard Platt, Jonathan H Watanabe, et al.
The American Journal of Cardiology|September 17, 2002
Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profileDean J Kereiakes, A Michael Lincoff, Keaven M Anderson, et al.
Medrxiv : the Preprint Server for Health Sciences|August 8, 2025
Racial and Ethnic Diversity in Clinical Studies Reported to ClinicalTrials.gov, 2009-2024Maryam Aziz, Emily C O'Brien, Jay B Lusk, et al.
American Heart Journal|September 14, 2002
Relationship between activated clotting time during percutaneous intervention and subsequent bleeding complicationsWilliam B Hillegass, Brigitta C Brott, Gregory D Chapman, et al.
Clinical Pharmacology and Therapeutics|May 1, 2021
When Can We Trust Real-World Data To Evaluate New Medical Treatments?Gregory E Simon, Andrew B Bindman, Nancy A Dreyer, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 10, 2013
The landscape of clinical trials in nephrology: a systematic review of Clinicaltrials.govJula K Inrig, Robert M Califf, Asba Tasneem, et al.
American Heart Journal|February 22, 2003
Development and validation of a simple model to predict severe coronary artery disease after myocardial infarction: potential impact on cardiac catheterization use in the United States and CanadaWayne B Batchelor, Daniel B Mark, J David Knight, et al.
Pageof 77